Each year, respiratory syncytial virus hospitalizes 58,000 to 80,000 children under age 5 in the U.S. The Food and Drug Administration recently approved an antibody injection for babies to protect them during the RSV season. There isn’t evidence the shots have killed any babies, contrary to social media claims.
Clinical trial data for Pfizer’s maternal vaccine to protect babies from RSV support the vaccine’s safety and efficacy, according to a vote by an FDA advisory committee. The FDA could soon approve the vaccine. But a popular social media post makes misleading claims about the trial findings.
Nearly all children get sick from respiratory syncytial virus, or RSV, by the age of 2, and last year, there was a notable surge in RSV-associated hospitalizations. But the Food and Drug Administration is now considering approval of a vaccine and a monoclonal antibody aimed at protecting infants from this common virus.
This year, the Food and Drug Administration will consider several applications for vaccines and a monoclonal antibody to prevent respiratory syncytial virus, or RSV, illness. We’ll go through some common questions about RSV and the potential vaccines for older adults in this story.
Hospitals across the country are seeing a spike of respiratory syncytial virus infections among children. Experts say the spike is most likely caused by an immunity gap created by the lack of exposure to the virus over the past couple of years. There’s no evidence the pediatric COVID-19 vaccine is the cause, as viral posts falsely claim.